Which intravenous antifungal is appropriate for a patient with end‑stage renal disease on dialysis?

Echinocandins are the preferred intravenous antifungal agents for patients with end-stage renal disease on dialysis

For patients with ESRD on dialysis requiring IV antifungal therapy, use an echinocandin (anidulafungin, micafungin, or caspofungin) without dose adjustment. These agents do not require renal dose adjustment and avoid the nephrotoxic and accumulation concerns associated with other antifungal classes in this population 1.

Specific Dosing Recommendations

First-Line Echinocandins (No Dose Adjustment Needed):

• Anidulafungin: 200 mg loading dose, then 100 mg daily 1
• Micafungin: 100 mg daily (or 150 mg for esophageal candidiasis) 1
• Caspofungin: 70 mg loading dose, then 50 mg daily 1

All three echinocandins are equally appropriate and require no dose modification for renal dysfunction or dialysis 1.

Why Echinocandins Over Other Options

Avoid IV Fluconazole in ESRD:

While fluconazole is renally cleared and requires dose adjustment in renal failure, the guidelines recommend it for specific scenarios 1. However, research shows fluconazole was associated with higher rates of acute kidney injury compared to other agents in patients with compromised renal function 2.

Avoid IV Voriconazole in ESRD:

The IV formulation contains sulfobutylether-β-cyclodextrin (SBECD), which accumulates significantly in renal failure. Even with daily hemodialysis, SBECD exposure exceeds normal levels by 6.2-fold 3. While voriconazole itself is minimally removed by dialysis, SBECD accumulation poses theoretical toxicity risks 3. Use oral voriconazole if this agent is specifically needed (e.g., for aspergillosis), as the oral formulation lacks SBECD.

Amphotericin B Considerations:

• Amphotericin B deoxycholate can be used intradialytically at 0.5-1.0 mg/kg three times weekly and has been shown safe and effective 4
• Liposomal amphotericin B is preferred over conventional formulations when amphotericin is indicated, given improved tolerability 5
• However, amphotericin carries inherent nephrotoxicity concerns and infusion-related reactions, making echinocandins preferable when clinically appropriate

Clinical Decision Algorithm

For invasive candidiasis/candidemia in dialysis patients:

1. Start an echinocandin immediately (any of the three options) 1
2. No dose adjustment required regardless of dialysis schedule
3. Continue until clinical response, then consider step-down to oral fluconazole if isolate is susceptible 1

For aspergillosis or mold infections:

1. Use oral voriconazole (avoid IV formulation due to SBECD) 3
2. Alternative: Liposomal amphotericin B 5 mg/kg daily 5

For urinary candidiasis:

1. Fluconazole 200-400 mg daily with dose adjustment for residual renal function 1
2. For fluconazole-resistant species: Amphotericin B deoxycholate 0.3-0.6 mg/kg intradialytically 1, 4

Key Pitfalls to Avoid

• Do not use IV voriconazole in dialysis patients due to SBECD accumulation; use oral formulation instead 3
• Do not underdose echinocandins thinking dose adjustment is needed—full standard doses are appropriate 1
• Do not delay therapy in septic patients waiting for cultures; empiric echinocandin therapy should start immediately in critically ill dialysis patients with suspected invasive candidiasis 1
• Monitor for drug interactions with caspofungin (affected by rifampin, phenytoin, carbamazepine), though anidulafungin and micafungin have fewer interactions

The evidence strongly supports echinocandins as the safest and most effective IV antifungal class for dialysis patients, with no pharmacokinetic concerns related to renal dysfunction 1, 2.